Page 84 - OR-1-1

86. Kim JT, Kim TY, Youn DH, et al. Human embryonic stem Mechanisms of immunomodulation in human glioblastoma.
cell-derived cerebral organoids for treatment of mild Immunotherapy. 2011;3(4 Suppl):42-44.
traumatic brain injury in a mouse model. Biochem Biophys doi: 10.2217/imt.11.39
Res Commun. 2022;635:169-178.
98. Friese MA, Platten M, Lutz SZ, et al. MICA/NKG2D-
doi: 10.1016/j.bbrc.2022.10.045
mediated immunogene therapy of experimental gliomas.
87. Lim SH, Jung H, Youn DH, et al. Mild traumatic brain injury Cancer Res. 2003;63(24):8996-9006.
and subsequent acute pulmonary inflammatory response. 99. Kepp O, Loos F, Liu P, Kroemer G. Extracellular nucleosides
J Korean Neurosurg Soc. 2022;65(5):680-687.
and nucleotides as immunomodulators. Immunol Rev.
doi: 10.3340/jkns.2021.0310 2017;280(1):83-92.
88. Kim JT, Song K, Han SW, et al. Modeling of the brain-lung doi: 10.1111/imr.12571
axis using organoids in traumatic brain injury: An updated 100. Shahar T, Rozovski U, Hess KR, et al. Percentage of mesenchymal
review. Cell Biosci. 2024;14(1):83.
stem cells in high-grade glioma tumor samples correlates with
doi: 10.1186/s13578-024-01252-2 patient survival. Neuro Oncol. 2017;19(5):660-668.
89. Wang P, Jin L, Zhang M, et al. Blood-brain barrier injury and doi: 10.1093/neuonc/now239
neuroinflammation induced by SARS-CoV-2 in a lung-brain 101. Autier L, Clavreul A, Cacicedo ML, et al. A new glioblastoma
microphysiological system. Nat Biomed Eng. 2024;8(8):1053-1068.
cell trap for implantation after surgical resection. Acta
doi: 10.1038/s41551-023-01054-w Biomater. 2019;84:268-279.
90. Popernack ML, Gray N, Reuter-Rice K. Moderate-to-severe doi: 10.1016/j.actbio.2018.11.027
traumatic brain injury in children: Complications and 102. Kasapidou PM, de Montullé EL, Dembélé KP, et al. Hyaluronic
rehabilitation strategies. J Pediatr Health Care. 2015;29(3):e1-e7.
acid-based hydrogels loaded with chemoattractant and
doi: 10.1016/j.pedhc.2014.09.003 anticancer drug - new formulation for attracting and tackling
glioma cells. Soft Matter. 2021;17(48):10846-10861.
91. Erices JI, Bizama C, Niechi I, et al. Glioblastoma
microenvironment and invasiveness: New insights and doi: 10.1039/d1sm01003d
therapeutic targets. Int J Mol Sci. 2023;24(8):7047.
103. Gould SE, Junttila MR, de Sauvage FJ. Translational value
doi: 10.3390/ijms24087047 of mouse models in oncology drug development. Nat Med.
2015;21(5):431-439.
92. Bikfalvi A, da Costa CA, Avril T, et al. Challenges
in glioblastoma research: Focus on the tumor doi: 10.1038/nm.3853
microenvironment. Trends Cancer. 2023;9(1):9-27.
104. Perrin S. Preclinical research: Make mouse studies work.
doi: 10.1016/j.trecan.2022.09.005 Nature. 2014;507(7493):423-425.
93. Tchoghandjian A, Baeza-Kallee N, Beclin C, et al. doi: 10.1038/507423a
Cortical and subventricular zone glioblastoma-derived 105. Pollard SM, Yoshikawa K, Clarke ID, et al. Glioma stem
stem-like cells display different molecular profiles and cell lines expanded in adherent culture have tumor-specific
differential in vitro and in vivo properties. Ann Surg Oncol. phenotypes and are suitable for chemical and genetic screens.
2012;19(Suppl 3):S608-S619.
Cell Stem Cell. 2009;4(6):568-580.
doi: 10.1245/s10434-011-2093-5
doi: 10.1016/j.stem.2009.03.014
94. Carlson JC, Cantu Gutierrez M, Lozzi B, et al. Identification 106. Pasupuleti V, Vora L, Prasad R, Nandakumar DN, Khatri DK.
of diverse tumor endothelial cell populations in malignant Glioblastoma preclinical models: Strengths and weaknesses.
glioma. Neuro Oncol. 2021;23(6):932-944.
Biochim Biophys Acta Rev Cancer. 2024;1879(1):189059.
doi: 10.1093/neuonc/noaa297
doi: 10.1016/j.bbcan.2023.189059
95. Jhaveri N, Chen TC, Hofman FM. Tumor vasculature and 107. Vaubel RA, Tian S, Remonde D, et al. Genomic and
glioma stem cells: Contributions to glioma progression. phenotypic characterization of a broad panel of patient-
Cancer Lett. 2016;380(2):545-551. derived xenografts reflects the diversity of glioblastoma. Clin
doi: 10.1016/j.canlet.2014.12.028 Cancer Res. 2020;26(5):1094-1104.
96. Cui J, Wang X, Li J, et al. Immune exosomes loading self- doi: 10.1158/1078-0432.CCR-19-0909
assembled nanomicelles traverse the blood-brain barrier 108. Golebiewska A, Hau AC, Oudin A, et al. Patient-derived
for chemo-immunotherapy against glioblastoma. ACS organoids and orthotopic xenografts of primary and
Nano. 2023.
recurrent gliomas represent relevant patient avatars for
doi: 10.1021/acsnano.2c10219 precision oncology. Acta Neuropathol. 2020;140(6):919-949.
97. Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V. doi: 10.1007/s00401-020-02226-7

Volume 1 Issue 1 (2025) 18 doi: 10.36922/or.8261